Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 6/20 | 0.41 |
| ▸ | HTR1D | P28221 | 3/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 5/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | DRD5 | P21918 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | HTR1B | P28222 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3157558 | 0.79 | RAB9A (0.40) | CA1CA2 | |
| SCHEMBL3163095 | 0.75 | CHRNA7 (0.47) | DRD2DRD3CA1CA2DRD4 | |
| SCHEMBL3158661 | 0.74 | DRD2 (0.44) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL31435300 | 0.73 | EPAS1 (0.40) | DRD2DRD3HTR1DAKR1C3CA1 | |
| SCHEMBL15318963 | 0.72 | DRD2 (0.40) | DRD2DRD3HTR1DAKR1C3CA1 | |
| SCHEMBL3154771 | 0.72 | CHRNB2 (0.50) | CA1CA2 | |
| SCHEMBL10214251 | 0.71 | DRD2 (0.42) | DRD2DRD3HTR1DCA1CA2 | |
| SCHEMBL28504373 | 0.70 | HTR6 (0.44) | DRD2DRD3HTR1DAKR1C3DRD4 | |
| SCHEMBL8618855 | 0.69 | MAOB (0.45) | HTR1DCA1CA2HTR1AHTR1B | |
| SCHEMBL10247310 | 0.69 | DRD2 (0.61) | DRD2DRD3HTR1DCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076325-B2 | 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-12-13 | — | — | US | disclosed |
| EP-2036892-B1 | 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2010-03-10 | — | — | EP | disclosed |
| EP-2036892-A1 | 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-03-18 | — | — | EP | disclosed |
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | OXER1, NR1H3, OXSR1 | DRD2 332/4885DRD3 357/4885HTR1D 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.